Paper42439331
Mechanistic Study of Yibi Decoction in Treating Rheumatoid Arthritis via Modulating the JAK2/STAT3 Signaling Pathway.
Huang C and 3 others. Endocr Metab Immune Disord Drug Targets, 2026. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Mechanistic Study of Yibi Decoction in Treating Rheumatoid Arthritis via Modulating the JAK2/STAT3 Signaling Pathway. Papers, record 42439331. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/42439331
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Mechanistic Study of Yibi Decoction in Treating Rheumatoid Arthritis via Modulating the JAK2/STAT3 Signaling Pathway.
- PubMed
Topics12
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Arthritis, Rheumatoid | Major topic |
| Janus Kinase 2 | Major topic |
| STAT3 Transcription Factor | Major topic |
| Arthritis, Experimental | Major topic |
| Drugs, Chinese Herbal | Major topic |
| Antirheumatic Agents | Major topic |
| Animals | |
| Signal Transduction | |
| Rats | |
| Male | |
| Network Pharmacology | |
| Rats, Sprague-Dawley |
Source PubMed
References75
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 39760183 | Inhibition of ASIC1a reduces ferroptosis in rheumatoid arthritis articular chondrocytes via the p53/NRF2/SLC7A11 pathway. | FASEB J | 2025 | https://conductscience.org/library/papers/39760183 | PubMed |
| 2 | 37685766 | Interleukin-23 Involved in Fibrotic Autoimmune Diseases: New Discoveries. | J Clin Med | 2023 | https://conductscience.org/library/papers/37685766 | PubMed |
| 3 | 34869276 | A Three-Dimensional Co-Culture Model for Rheumatoid Arthritis Pannus Tissue. | Front Bioeng Biotechnol | 2021 | https://conductscience.org/library/papers/34869276 | PubMed |
| 4 | 35705856 | Mechanisms of joint destruction in rheumatoid arthritis - immune cell-fibroblast-bone interactions. | Nat Rev Rheumatol | 2022 | https://conductscience.org/library/papers/35705856 | PubMed |
| 5 | 31948481 | A benchmark of batch-effect correction methods for single-cell RNA sequencing data. | Genome Biol | 2020 | https://conductscience.org/library/papers/31948481 | PubMed |
| 6 | 38240831 | Rheumatoid arthritis. | Lancet | 2023 | https://conductscience.org/library/papers/38240831 | PubMed |
| 7 | 35782030 | Comparison of treatment of severe rheumatoid arthritis patients with biological agents and JAK-STAT inhibitors. An observational study. | Reumatologia | 2022 | https://conductscience.org/library/papers/35782030 | PubMed |
| 8 | 32079226 | Role of Signal Transduction Pathways and Transcription Factors in Cartilage and Joint Diseases. | Int J Mol Sci | 2020 | https://conductscience.org/library/papers/32079226 | PubMed |
| 9 | 30941350 | Synovial Tissue Heterogeneity in Rheumatoid Arthritis and Changes With Biologic and Targeted Synthetic Therapies to Inform Stratified Therapy. | Front Med (Lausanne) | 2019 | https://conductscience.org/library/papers/30941350 | PubMed |
| 10 | 40074996 | Pharmacological modes of plant-derived compounds for targeting inflammation in rheumatoid arthritis: A comprehensive review on immunomodulatory perspective. | Inflammopharmacology | 2025 | https://conductscience.org/library/papers/40074996 | PubMed |
| 11 | 30001781 | Pharmacotherapy Pearls in Rheumatology for the Care of Older Adult Patients: Focus on Oral Disease-Modifying Antirheumatic Drugs and the Newest Small Molecule Inhibitors. | Rheum Dis Clin North Am | 2018 | https://conductscience.org/library/papers/30001781 | PubMed |
| 12 | 37014106 | JAK inhibitors for rheumatoid arthritis. | Expert Opin Investig Drugs | 2023 | https://conductscience.org/library/papers/37014106 | PubMed |
| 13 | 39237134 | Generation of cytotoxic aptamers specifically targeting fibroblast-like synoviocytes by CSCT-SELEX for treatment of rheumatoid arthritis. | Ann Rheum Dis | 2025 | https://conductscience.org/library/papers/39237134 | PubMed |
| 14 | 36618407 | Systemic complications of rheumatoid arthritis: Focus on pathogenesis and treatment. | Front Immunol | 2022 | https://conductscience.org/library/papers/36618407 | PubMed |
| 15 | 38727279 | Clinical Phenotypes, Serological Biomarkers, and Synovial Features Defining Seropositive and Seronegative Rheumatoid Arthritis: A Literature Review. | Cells | 2024 | https://conductscience.org/library/papers/38727279 | PubMed |
| 16 | 33482191 | The role of myeloid-derived suppressor cells in rheumatoid arthritis: An update. | Life Sci | 2021 | https://conductscience.org/library/papers/33482191 | PubMed |
| 17 | 40684897 | Managing the clinical heterogeneity of patients with Still's disease, from early diagnosis to timely treatment. | Autoimmun Rev | 2025 | https://conductscience.org/library/papers/40684897 | PubMed |
| 18 | 35400377 | Rheumatoid Arthritis: Early Diagnosis and Treatment. | Rheum Dis Clin North Am | 2022 | https://conductscience.org/library/papers/35400377 | PubMed |
| 19 | 40561673 | Cellular interactions in maintaining an inflammatory microenvironment in rheumatoid arthritis. | Mol Immunol | 2025 | https://conductscience.org/library/papers/40561673 | PubMed |
| 20 | 39278299 | Targeting ferroptosis in autoimmune diseases: Mechanisms and therapeutic prospects. | Autoimmun Rev | 2024 | https://conductscience.org/library/papers/39278299 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/42439331
GET https://conductscience.org/api/papers/v1/42439331/references?page=2